Patents by Inventor Carel A. Van Baalen

Carel A. Van Baalen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070087333
    Abstract: The invention relates to a novel non-radioactive method to detect cytolytic activity that provides a measure of the existence and magnitude of an immune response against a particular antigen or immunogen. Provided is a method for detecting cytolytic activity of cells or a substance against a population of target cells, comprising the steps of providing target cells with a first nucleic acid sequence encoding a reporter molecule and a second nucleic acid sequence encoding an antigen of interest; co-culturing the target cells with a sample containing cells or a substance suspected of having cytolytic activity; and detecting the viability of target cells provided with the reporter molecule. Also provided are a kit and a nucleic acid for use in a method according to the invention.
    Type: Application
    Filed: August 18, 2006
    Publication date: April 19, 2007
    Applicant: Erasmus Universiteit Rotterdam
    Inventors: Robertus Gruters, Carel van Baalen, Gustaaf Rimmelzwaan, Albertus Dominicus Marcellinus Osterhaus
  • Patent number: 6319666
    Abstract: The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favorable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: November 20, 2001
    Assignee: Erasmus Universiteit Rotterdam
    Inventors: Carel A. Van Baalen, Albertus D.M.E. Osterhaus
  • Patent number: 6024965
    Abstract: The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: February 15, 2000
    Assignee: Erasums University Rotterdam
    Inventors: Carel A. van Baalen, Albertus D. M. E. Osterhaus
  • Patent number: 5942401
    Abstract: The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: August 24, 1999
    Assignee: Connaught Laboratories Limited
    Inventors: Carel A. van Baalen, Albertus D. M. E. Osterhaus